Disclaimers

No Approved Product

BMX-001 and all other BioMimetix product candidates are investigational. BioMimetix does not have any product approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority worldwide. All clinical results described herein are from ongoing or completed clinical trials and do not constitute evidence of safety or efficacy for any approved use. There is no guarantee that any product candidate will receive regulatory approval or be successfully commercialized.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of applicable securities laws, including statements regarding clinical development plans, regulatory pathways, market opportunities, and anticipated milestones. These statements involve risks, uncertainties, and assumptions that could cause actual results to differ materially. Past clinical results do not guarantee future performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this communication.

Not an Offer of Securities

Nothing contained in this communication constitutes, or should be construed as, an offer to sell, or a solicitation of an offer to buy, any security, instrument, or investment interest. Any offering of securities, if and when made, will be made only to qualified investors through definitive offering documents containing complete information about risks and investment considerations.

Information Accuracy & Non-Confidential

The information presented is non-confidential and provided for informational purposes only. While BioMimetix believes the information to be reliable, it makes no representation or warranty, express or implied, as to its accuracy or completeness. Clinical data are drawn from the cited sources; readers are directed to the References section for primary documentation.

FDA Breakthrough Therapy Designation

A regulatory status intended to expedite development and review of drugs for serious conditions. It is not an approval, and does not guarantee that BMX-001 will be approved or that any specific outcome will result. Breakthrough Therapy, Fast Track, and Orphan Drug designations all apply to the glioma indication only.

Copyright & Content Ownership

All content on this site — including text, graphics, logos, images, data visualizations, and clinical information — is the property of BioMimetix, Inc. and is protected by United States and international copyright laws. No part of this material may be reproduced, distributed, or transmitted in any form or by any means without the prior written permission of BioMimetix, Inc., except as permitted by applicable law.

Clinical photography is sourced from Unsplash and is used under the Unsplash License; it is for illustrative purposes only and does not depict actual BioMimetix trial participants.